source
- Anaconda Biomed snares $56M in funding for endovascular techMedtech startup Anaconda Biomed has hauled in $53 million to help finish off work on a pivotal trial for its endovascular project.
- Vertex opens up larger kidney disease opportunity with mid-stage readoutWhile Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…BioSpace · 1mo ago↗ source
- Telix to acquire ITM Isotope Technologies for $1.65 billion, adding late-stage radiopharma asset ITM-11